AA
SIOX

ALPS Advisors’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

ALPS Advisors’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,237
Closed -$729K – 893
2017
Q3 		$729K Buy
13,237
+1,288
+11% +$217K 0.01% 304
2017
Q2 		$2.22M Buy
11,949
+1,285
+12% +$225K 0.02% 181
2017
Q1 		$1.27M Sell
10,664
-1,248
-10% -$131K 0.01% 200
2016
Q4 		$1.18M Sell
11,912
-3,890
-25% -$410K 0.01% 207
2016
Q3 		$1.77M Sell
15,802
-1,609
-9% -$193K 0.01% 190
2016
Q2 		$1.79M Buy
17,411
+3,473
+25% +$347K 0.02% 176
2016
Q1 		$1.28M Sell
13,938
-2,389
-15% -$255K 0.01% 176
2015
Q4 		$2.35M Buy
+16,327
New +$2.12M 0.02% 164

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ALPS Advisors's SIOX Position: Q4 2017 in Review

ALPS Advisors sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2017, closing a stake of 13,237 shares — an estimated $729K sold.

ALPS Advisors first reported a position in SIOX in Q4 2015 and held it in 8 quarters. The position peaked at $2.35M in Q4 2015. 104 funds tracked by Wall St. Rank hold SIOX as of Q4 2017.

  • ALPS Advisors reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • ALPS Advisors sold 13,237 Sio Gene Therapies Inc. Common Stock shares in Q4 2017, an estimated $729K.
  • ALPS Advisors first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2015 and held it in 8 quarters.
  • ALPS Advisors's Sio Gene Therapies Inc. Common Stock position peaked at $2.35M in Q4 2015.
  • 104 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2017.

Based on ALPS Advisors's 13F filing for Q4 2017, filed 5 Feb 2018.